Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-marrow mesenchymal stromal cell transplantation for lower-risk myelodysplastic syndromes
NL-OMON37006Phase 2Withdrawn
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2012
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of Provacel in myelodysplastic syndrome (MDS) (4 arms), sponsored by Radboud University Medical Center. Primary endpoint: Safety of intra-marrow transplantation of mesenchymal stromal cells. Planned start Sep 2012; status: withdrawn.
02
Drugs
Provacel
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON37006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37006.